A Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON Study.

Details

Ressource 1Download: 38584069.pdf (2487.05 [Ko])
State: Public
Version: Final published version
License: CC BY-NC-ND 4.0
Serval ID
serval:BIB_7A92BC1E6EB4
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
A Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON Study.
Journal
Clinical lung cancer
Author(s)
Garon E.B., Cho B.C., Luft A., Alatorre-Alexander J., Geater S.L., Trukhin D., Kim S.W., Ursol G., Hussein M., Lim F.L., Yang C.T., Araujo L.H., Saito H., Reinmuth N., Kohlmann M., Lowery C., Mann H., Peters S., Mok T.S., Johnson M.L.
ISSN
1938-0690 (Electronic)
ISSN-L
1525-7304
Publication state
Published
Issued date
05/2024
Peer-reviewed
Oui
Volume
25
Number
3
Pages
266-273.e5
Language
english
Notes
Publication types: Journal Article ; Clinical Trial, Phase III
Publication Status: ppublish
Keywords
Humans, Carcinoma, Non-Small-Cell Lung/drug therapy, Carcinoma, Non-Small-Cell Lung/pathology, Lung Neoplasms/drug therapy, Lung Neoplasms/pathology, Antibodies, Monoclonal, Humanized/administration & dosage, Antibodies, Monoclonal, Humanized/therapeutic use, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Antibodies, Monoclonal/administration & dosage, Antibodies, Monoclonal/therapeutic use, B7-H1 Antigen/metabolism, B7-H1 Antigen/antagonists & inhibitors, Male, Female, Treatment Outcome, Clinical trial, Cytotoxic T-lymphocyte-associated antigen 4, Immune checkpoint inhibitor, Immunotherapy, Programmed cell death ligand-1
Pubmed
Open Access
Yes
Create date
12/04/2024 9:16
Last modification date
21/05/2024 8:34
Usage data